3Sbio Overview
- Year Founded
-
1993
- Status
-
Public
- Employees
-
6,068
- Stock Symbol
-
01530
- Investments
-
22
- Share Price
-
$1.62
- (As of Friday Closing)
3Sbio General Information
Description
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.
Contact Information
Website
www.3sbio.comCorporate Office
- 1st 3, 10th Road
- Economic and Technological Development Zone
- Shenyang, Liaoning
- China
Corporate Office
- 1st 3, 10th Road
- Economic and Technological Development Zone
- Shenyang, Liaoning
- China
3Sbio Stock Performance
As of 20-Nov-2026, 3Sbio’s stock price is $1.62. Its current market cap is $4.01B with 2.48B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.62 | $1.68 | $1.59 - $4.22 | $4.01B | 2.48B | 19.5M | $0.48 |
3Sbio Financials Summary
As of 30-Jun-2026, 3Sbio has a trailing 12-month revenue of $2.55B.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,452,368 | 7,122,518 | 1,992,945 | 2,450,513 |
| Revenue | 2,553,284 | 2,460,709 | 1,269,323 | 1,104,745 |
| EBITDA | 1,453,597 | 1,536,730 | 439,846 | 335,338 |
| Net Income | 1,181,954 | 1,179,500 | 291,315 | 218,977 |
| Total Assets | 5,236,510 | 5,181,062 | 3,316,768 | 3,332,820 |
| Total Debt | 204,165 | 374,155 | 486,898 | 682,482 |
3Sbio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
3Sbio Comparisons
Industry
Financing
Details
3Sbio Competitors (43)
One of 3Sbio’s 43 competitors is Abbisko Medicine, a Formerly VC-backed company based in Shanghai, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Abbisko Medicine | Formerly VC-backed | Shanghai, China | ||||
| Alphamab Oncology | Formerly VC-backed | Suzhou, China | ||||
| Innovent Biologics | Formerly VC-backed | Suzhou, China | ||||
| Pfizer | Corporation | New York, NY | ||||
| Takeda Pharmaceutical | Corporation | Tokyo, Japan |
3Sbio Signals
3Sbio Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
3Sbio Investments & Acquisitions (22)
3Sbio’s most recent deal was a Later Stage VC with Xellsmart. The deal was made on 25-Feb-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Xellsmart | 25-Feb-2026 | Later Stage VC | Drug Discovery | ||
| Xellsmart | 14-Jan-2026 | Later Stage VC | Drug Discovery | ||
| Sain Biotechnology | 30-Oct-2025 | Corporate | Drug Discovery | ||
| Enkai Cell Technology | 22-Nov-2024 | Early Stage VC | Drug Discovery | ||
| C-Ray | 09-Sep-2024 | Early Stage VC | Drug Discovery |
3Sbio ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
27.14 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
3Sbio Exits (4)
3Sbio’s most recent exit was on 28-Jun-2019 from InnoBio. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| InnoBio | 28-Jun-2019 | Completed |
|
||
| Refuge Biotech | 02-May-2018 | Completed |
|
||
| Zhejiang Sunshine Mandi Pharmaceutical | 29-Jul-2015 | Completed |
|
||
| Ascentage Pharma | 11-Feb-2010 | Corporate | Completed |
3Sbio Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Sciprogen Bio-pharmaceutical | Shenzhen, China | 1999 |
3Sbio FAQs
-
When was 3Sbio founded?
3Sbio was founded in 1993.
-
Where is 3Sbio headquartered?
3Sbio is headquartered in Shenyang, China.
-
What is the size of 3Sbio?
3Sbio has 6,068 total employees.
-
What industry is 3Sbio in?
3Sbio’s primary industry is Pharmaceuticals.
-
Is 3Sbio a private or public company?
3Sbio is a Public company.
-
What is 3Sbio’s stock symbol?
The ticker symbol for 3Sbio is 01530.
-
What is the current stock price of 3Sbio?
As of 20-Nov-2026 the stock price of 3Sbio is $1.62.
-
What is the current market cap of 3Sbio?
The current market capitalization of 3Sbio is $4.01B.
-
What is 3Sbio’s current revenue?
The trailing twelve month revenue for 3Sbio is $2.55B.
-
Who are 3Sbio’s competitors?
Abbisko Medicine, Alphamab Oncology, Innovent Biologics, Pfizer, and Takeda Pharmaceutical are some of the 43 competitors of 3Sbio.
-
What is 3Sbio’s annual earnings per share (EPS)?
3Sbio’s EPS for 12 months was $0.48.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process